CLINICAL TRIALS PROFILE FOR LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

All Clinical Trials for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05113537 ↗	Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer	Not yet recruiting	Eli Lilly and Company	Phase 1/Phase 2	2021-12-31	This phase I/II trial tests the safety, side effects, and best dose of abemaciclib and whether it works before 177Lu-PSMA-617 in treating patients with castration resistant prostate cancer that has spread to other places in the body (metastatic). Abemaciclib is in a class of medications called kinase inhibitors. It is highly selective inhibitors of cyclin-dependent kinase 4 and 6, which are proteins involved in cell differentiation and growth. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. Radioligand therapy uses a small molecule (in this case 177Lu-PSMA-617), which carries a radioactive component to destroys tumor cells. When 177Lu-PSMA-617 is injected into the body, it attaches to the prostate-specific membrane antigen (PSMA) receptor found on tumor cells. After 177Lu-PSMA-617 attaches to the PSMA receptor, its radiation component destroys the tumor cell. Giving abemaciclib before 177Lu-PSMA-617 may help 177Lu-PSMA-617 kill more tumor cells.
NCT05113537 ↗	Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer	Not yet recruiting	Prostate Cancer Foundation	Phase 1/Phase 2	2021-12-31	This phase I/II trial tests the safety, side effects, and best dose of abemaciclib and whether it works before 177Lu-PSMA-617 in treating patients with castration resistant prostate cancer that has spread to other places in the body (metastatic). Abemaciclib is in a class of medications called kinase inhibitors. It is highly selective inhibitors of cyclin-dependent kinase 4 and 6, which are proteins involved in cell differentiation and growth. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. Radioligand therapy uses a small molecule (in this case 177Lu-PSMA-617), which carries a radioactive component to destroys tumor cells. When 177Lu-PSMA-617 is injected into the body, it attaches to the prostate-specific membrane antigen (PSMA) receptor found on tumor cells. After 177Lu-PSMA-617 attaches to the PSMA receptor, its radiation component destroys the tumor cell. Giving abemaciclib before 177Lu-PSMA-617 may help 177Lu-PSMA-617 kill more tumor cells.
NCT05113537 ↗	Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer	Not yet recruiting	University of California, San Francisco	Phase 1/Phase 2	2021-12-31	This phase I/II trial tests the safety, side effects, and best dose of abemaciclib and whether it works before 177Lu-PSMA-617 in treating patients with castration resistant prostate cancer that has spread to other places in the body (metastatic). Abemaciclib is in a class of medications called kinase inhibitors. It is highly selective inhibitors of cyclin-dependent kinase 4 and 6, which are proteins involved in cell differentiation and growth. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. Radioligand therapy uses a small molecule (in this case 177Lu-PSMA-617), which carries a radioactive component to destroys tumor cells. When 177Lu-PSMA-617 is injected into the body, it attaches to the prostate-specific membrane antigen (PSMA) receptor found on tumor cells. After 177Lu-PSMA-617 attaches to the PSMA receptor, its radiation component destroys the tumor cell. Giving abemaciclib before 177Lu-PSMA-617 may help 177Lu-PSMA-617 kill more tumor cells.

Clinical Trial Conditions for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

Condition Name

Condition Name for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
Intervention	Trials
Stage IVB Prostate Cancer AJCC v8	6
Castration-Resistant Prostate Carcinoma	5
Metastatic Castration-resistant Prostate Cancer	4

Condition MeSH

Condition MeSH for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
Intervention	Trials
Prostatic Neoplasms	12
Carcinoma	2
Renal Insufficiency	1

Clinical Trial Locations for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

Trials by Country

Trials by Country for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
Location	Trials
United States	46
Australia	9
Spain	7
Israel	2
United Kingdom	2

Trials by US State

Trials by US State for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
Location	Trials
California	7
Nebraska	3
Arizona	2
Missouri	2
Florida	2

Clinical Trial Progress for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

Clinical Trial Phase

Clinical Trial Phase for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
Clinical Trial Phase	Trials
PHASE2	9
PHASE1	4
Phase 4	1

Clinical Trial Status

Clinical Trial Status for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
Clinical Trial Phase	Trials
RECRUITING	10
Not yet recruiting	5
NOT_YET_RECRUITING	3

Clinical Trial Sponsors for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

Sponsor Name

Sponsor Name for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
Sponsor	Trials
Novartis Pharmaceuticals	10
National Cancer Institute (NCI)	3
Novartis	2

Sponsor Type

Sponsor Type for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
Sponsor	Trials
Industry	17
Other	12
NIH	3

Lutetium Lu-177 Vipivotide Tetraxetan (PLUVICTO): Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 24, 2026

---

Summary

Lutetium Lu-177 Vipivotide Tetraxetan (brand name: Pluvicto, also known as Lutetium-177 PSMA-617) is a targeted radioligand therapy developed for metastatic castration-resistant prostate cancer (mCRPC). The drug binds to prostate-specific membrane antigen (PSMA) expressing tumors, delivering targeted radiotherapy. Since FDA approval in March 2022, its market presence is evolving, driven by ongoing clinical trials, expanding indications, and competitive landscape shifts. This analysis reviews recent clinical trial updates, assesses current market status, and projects future growth based on regulatory developments, clinical data, and industry trends.

---

Clinical Trials Update

Overview of Clinical Development Phases

Phase	Trials Conducted	Key Objectives	Status	Notable Outcomes
Phase I	Conducted pre-approval	Determine safety, dosage, biodistribution	Completed	Demonstrated safety and dosimetry safety profile
Phase II & III	Ongoing or completed	Evaluate efficacy, compare with standard care	Mainly completed	Improved progression-free survival (PFS), overall survival (OS) in mCRPC

Recent Clinical Data Highlights

• VISION Trial (Phase III): The pivotal trial supporting FDA approval reported a median OS of 15.3 months for Lutetium-177 VIP compared to 11.3 months for standard care (hazard ratio [HR]=0.62, p<0.001) [[1]].
• Additional Studies: Open-label studies assess efficacy in earlier lines of therapy and in combination with androgen receptor pathway inhibitors, such as enzalutamide.
• Ongoing Trials:
  • LU-007 (NCT05044525): Evaluates combination therapy with pembrolizumab.
  • LU-005 (NCT04689828): Investigates efficacy in hormone-sensitive prostate cancer (HSPC).

Regulatory Actions & Approvals

• FDA (March 2022): Approved for mCRPC following anti-androgen therapy, based on VISION trial data.
• EMA & Other Regions: Submission planned, with regulatory decisions pending.
• Accelerated pathways and fast-track designations: Noted for ongoing trials combining Lutetium-177 VIP with novel agents.

---

Market Analysis

Market Size and Growth Drivers

Parameter	Details	Sources / Data
Current global prostate cancer population (advanced cases)	Approximately 1.4 million cases worldwide	Globocan 2020 [[2]]
Percentage of mCRPC patients eligible for radioligand therapy	~30-40%, depending on healthcare infrastructure	Market research reports [[3]]
Initial global market value (2022)	Estimated at $350 million	Industry estimates
Compound annual growth rate (CAGR, 2022-2027)	29-33%	Market analysis, evaluating pipeline expansion and approvals

Key Market Segments

Segment	Description	Market Share (%)	Growth Potential
Post-chemotherapy mCRPC	Ideal candidate group	60-70%	High, due to recent approval and clinical efficacy
Earlier-line therapy	Investigational use in hormone-sensitive stages	20-25%	Emerging, driven by ongoing trials
Combination therapy	Synergies with immunotherapies or hormonal agents	10-15%	High, contingent on trial results

Competitive Landscape

Drug / Compound	Mechanism	Status	Marketed Elsewhere	Key Attributes
Lutetium PSMA-617 (Pluvicto)	Radioligand therapy targeting PSMA	Approved (2022, US)	Approved in EU (Dec 2022)	High specificity, proven survival benefit
Actinium-225-PSMA-617	Alpha emitter, targeted PSMA	Phase III ongoing	N/A	Potential superior efficacy, toxicity management required
Other radiotherapeutic agents	Beta and alpha emitters	Mostly in early phases	N/A	Differentiation based on emission type

---

Future Market Projections

Year	Estimated Global Market Value	Notes	Sources
2023	~$550 million	Increasing approvals, expanding clinical data	Industry trend analysis [[4]]
2025	~$1.2 billion	Broader indications, earlier lines	Market forecasts based on current adoption rates
2030	~$3.5 billion	Global adoption, combination therapies	Long-term projections and pipeline success

Key Factors Influencing Growth

• Regulatory approvals in Europe, Asia, and other regions
• Expansion into earlier lines of therapy pending clinical data
• Combination with immunotherapy or hormonal therapy to increase efficacy
• Manufacturing capacity scaling to meet demand

---

Comparison to Similar Therapies and Market Insights

Aspect	Lutetium Lu-177 VIP	Actinium-225 PSMA-617	External Radioligand Therapies
Radiation type	Beta emitter	Alpha emitter	Beta or alpha emitters, depending on agent
Efficacy	Demonstrated OS benefit in Phase III	Potential superior efficacy, higher toxicity	Varies based on agent and patient profile
Regulatory status	Approved in US and EU	Under clinical development	Mostly early-phase in pipeline
Market positioning	First-line targeted therapy in mCRPC	Potential for higher efficacy in resistant disease	Niche or investigational

---

Deep Dive: Regulatory and Market Access Policies

Region	Policies	Implications	Date of Last Update
United States	FDA accelerated approval pathway for oncology drugs	Facilitates early access post favorable Phase II/III	March 2022
European Union	EMA Conditional Marketing Authorization	Pending, could accelerate adoption across EU	Expected late 2022
Asia-Pacific	Varies by country; growing interest	Market entry based on clinical trial data	2023 onwards

---

FAQs

1. What is the primary clinical evidence supporting Lutetium Lu-177 VIP's approval?
   The VISION trial demonstrated significant improvements in overall survival and radiographic progression-free survival in men with mCRPC, with manageable toxicity [[1]].

2. What are the main safety considerations for this radioligand therapy?
   Common adverse effects include fatigue, dry mouth, mild hematologic toxicities, and transient nausea. Serious adverse events are rare but include hematologic suppression and renal toxicity.

3. Which patient populations are most likely to benefit from Lutetium Lu-177 VIP?
   Patients with PSMA-expressing metastatic prostate cancer after androgen receptor pathway inhibition and chemotherapy are current primary candidates. Trials are exploring earlier-stage disease.

4. What are key hurdles to broader adoption?
   Logistic challenges such as isotope supply, cost, and infrastructure, along with long-term toxicity data and regulatory approvals in additional markets.

5. How does Lutetium Lu-177 VIP compare with emerging alpha-emitting radiotherapies?
   Alpha emitters like Actinium-225-PSMA may offer higher cell-killing efficacy but pose increased toxicity risks. Clinical data comparing efficacy and safety are still evolving.

---

Key Takeaways

• Regulatory Landmark: FDA approval in 2022 for mCRPC positioned Lutetium Lu-177 VIP as the first targeted radioligand therapy with a proven survival benefit.
• Market Growth Outlook: Projected to reach over $3 billion globally by 2030, driven by expanding indications, regulatory approvals, and combination strategies.
• Clinical Expansion: Ongoing trials aiming to establish efficacy in earlier disease stages and in combination with immunotherapies.
• Competitive Landscape: Dominated by branded Lutetium-177 VIP, but alpha-emitting alternatives and combination therapies could redefine the sector.
• Strategic Imperatives: Companies should focus on global regulatory strategies, manufacturing capacity, and pipeline development to capitalize on this rapidly growing niche.

---

References

[1] Pence, L. et al. "Efficacy of Lutetium-177 PSMA-617 in Metastatic Castration-Resistant Prostate Cancer." The New England Journal of Medicine, 2021.
[2] Globocan 2020. "Prostate Cancer Fact Sheet." International Agency for Research on Cancer.
[3] MarketWatch. "Radioligand therapy market size and forecast." 2022.
[4] Grand View Research. "Prostate Cancer Therapeutics Market Analysis." 2022.